- Home
- LMAT vs DNLI Comparison
LMAT vs DNLI Comparison
Compare LMAT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMAT
- DNLI
- Stock Information
- Founded
- LMAT 1983
- DNLI 2013
- Country
- LMAT United States
- DNLI United States
- Employees
- LMAT N/A
- DNLI N/A
- Industry
- LMAT Medical/Dental Instruments
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LMAT Health Care
- DNLI Health Care
- Exchange
- LMAT Nasdaq
- DNLI Nasdaq
- Market Cap
- LMAT 1.9B
- DNLI 1.9B
- IPO Year
- LMAT 2006
- DNLI 2017
- Fundamental
- Price
- LMAT $80.40
- DNLI $13.96
- Analyst Decision
- LMAT Buy
- DNLI Strong Buy
- Analyst Count
- LMAT 7
- DNLI 15
- Target Price
- LMAT $100.67
- DNLI $33.85
- AVG Volume (30 Days)
- LMAT 225.6K
- DNLI 1.3M
- Earning Date
- LMAT 05-01-2025
- DNLI 07-31-2025
- Dividend Yield
- LMAT 1.00%
- DNLI N/A
- EPS Growth
- LMAT 30.45
- DNLI N/A
- EPS
- LMAT 1.97
- DNLI N/A
- Revenue
- LMAT $226,256,000.00
- DNLI N/A
- Revenue This Year
- LMAT $13.58
- DNLI N/A
- Revenue Next Year
- LMAT $8.81
- DNLI $256.73
- P/E Ratio
- LMAT $40.64
- DNLI N/A
- Revenue Growth
- LMAT 13.19
- DNLI N/A
- 52 Week Low
- LMAT $71.42
- DNLI $10.57
- 52 Week High
- LMAT $109.58
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- LMAT 43.38
- DNLI 49.11
- Support Level
- LMAT $80.54
- DNLI $12.86
- Resistance Level
- LMAT $82.78
- DNLI $13.77
- Average True Range (ATR)
- LMAT 2.36
- DNLI 0.77
- MACD
- LMAT -0.12
- DNLI -0.04
- Stochastic Oscillator
- LMAT 25.88
- DNLI 57.29
About LMAT LeMaitre Vascular Inc.
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.